FDA Approves Oral Testosterone Replacement Therapy Kyzatrex
The FDA has approved Kyzatrex (testosterone undecanoate) for the treatment of primary and secondary hypogonadism in adult males.
Hypogonadism
Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
Testosterone Replacement Therapy Tlando Now Available
Tlando is supplied as 112.5mg of testosterone undecanoate capsules.
FDA Approves Oral Testosterone Replacement Therapy Tlando
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Testosterone Therapy for Hypogonadism May Cut Risk for CV Events
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
COVID-19 Is Associated With Low Testosterone in Men
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
Kyzatrex Under Review for Primary and Secondary Male Hypogonadism
Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.
New Drug Product: Jatenzo
This slideshow shows drug information for Jatenzo. Click here for the complete Jatenzo monograph.
MPR Weekly Dose Podcast Episode 21
This week on the Pod we cover an insulin pump recall; Pharmacies running out of supplies in light of Covid-19 fears; Investigational Alzheimer disease treatments not meeting trial end points; A new cardiac ultrasound device; and a new oral testosterone replacement therapy.
